World Orphan Drug Congress Europe 2026

Bringing together more than 2,000 professionals—including scientists, policymakers, patient advocates, industry executives, and regulatory representatives—the congress spans the full orphan drug value chain. Topics include cell and gene therapy, genetic testing, market access, pricing, real-world evidence, regulatory policy, manufacturing, patient advocacy, and precision medicine. The format includes pre-congress workshops on the 26th followed by a two-day conference and exhibition on the 27th and 28th, featuring over 250 expert speakers and 130 exhibitors. Networking is a core component, with opportunities for 1‑to‑1 partnering meetings and broader engagement throughout the event. The congress is CPD-accredited, offering up to 26 CPD hours. Amsterdam’s established life sciences ecosystem and robust partner network reinforce the event’s role in shaping rare disease strategies and innovation.The World Orphan Drug Congress Europe 2026 brings together the most senior and informed industry experts across the entire orphan drug and rare disease landscape.

From basic research to commercial manufacture, this meeting covers the​ whole orphan drugs value chain where science, government and manufacturers all​ come together to create ground- breaking progress.​